Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors.
Suravi RayFels Cancer Institute for Personalized Medicine, Department of Cancer & Cellular Biology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, USA.ORCID 0009-0007-9713-2307
Jamie L McCallDepartment of Microbiology, Immunology & Cell Biology, West Virginia University School of Medicine, Morgantown, WV 26506, USA.ORCID 0000-0001-5914-6336
Jin Bin TianDepartment of Integrative Biology and Pharmacology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston TX 77030, USA.ORCID 0000-0002-5516-7778
Jaepyo JeonDepartment of Integrative Biology and Pharmacology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston TX 77030, USA.ORCID 0000-0002-0275-7395
Aidan DouglasFels Cancer Institute for Personalized Medicine, Department of Cancer & Cellular Biology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, USA.ORCID 0009-0004-4483-651X
Kendall TylerFels Cancer Institute for Personalized Medicine, Department of Cancer & Cellular Biology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, USA.
Siyao LiuCenter for Translational Cancer Research, Institute of Biosciences and Technology, Texas A&M University, Houston, TX 77030, USA.ORCID 0009-0000-0575-3835
Kendyl BerryDepartment of Microbiology, Immunology & Cell Biology, West Virginia University School of Medicine, Morgantown, WV 26506, USA.ORCID 0000-0001-8447-3881
Casey HallExesaLibero Pharma, Morgantown, WV 26505, USA.
Klaus GroschnerMedical University of Graz, Division of Medical Physics and Biophysics, Neue Stiftingtalstrasse 6/H03, 8010 Graz, Austria.ORCID 0000-0002-8659-377X
Bernadett BacsaMedical University of Graz, Division of Medical Physics and Biophysics, Neue Stiftingtalstrasse 6/H03, 8010 Graz, Austria.ORCID 0000-0003-2201-4721
Werner GeldenhuysDepartment of Pharmaceutical Sciences, West Virginia University School of Pharmacy, Morgantown, WV 26506, USA.ORCID 0000-0002-2405-376X
Michael X ZhuDepartment of Integrative Biology and Pharmacology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston TX 77030, USA.ORCID 0000-0002-5676-841X
Harry C BlairResearch Service, VA Medical Centre, Departments of Pathology and of Cell Biology, University of Pittsburgh, Pittsburgh, PA, 15261, USA.ORCID 0000-0002-1152-3718
John B BarnettDepartment of Microbiology, Immunology & Cell Biology, West Virginia University School of Medicine, Morgantown, WV 26506, USA.ORCID 0000-0001-6547-2381
Jonathan SoboloffFels Cancer Institute for Personalized Medicine, Department of Cancer & Cellular Biology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, USA.ORCID 0000-0001-5192-1297
Funding
West Virginia IDEA-CTRU54GM104942 · NIGMS · WEST VIRGINIA UNIVERSITY · PI Anne Courtney DeVries · 2012 to 2026
$81.0M
WV INBRE: The Inhibitor of Growth Family Member 4 (ING4) inhibits L-Type Amino Acid Transporter 1 (LAT1) expression to suppress Breast CancerP20GM103434 · NIGMS · MARSHALL UNIVERSITY · PI GARY O RANKIN · 2012 to 2026
$61.1M
West Virginia University Stroke COBREP20GM109098 · NIGMS · WEST VIRGINIA UNIVERSITY · PI DEVRIES, ANNE COURTNEY · 2014 to 2024
$24.5M
WVU Flow Cytometry and Single Cell Core Facility (FCSCCF)P20GM121322 · NIGMS · WEST VIRGINIA UNIVERSITY · PI Karen H Martin · 2018 to 2026
$22.4M
Epithelial Osteoblast Function: The Role of Acid TransportR01AR076146 · NIAMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BLAIR, HARRY COLBERT, NELSON, DEBORAH J. · 2020 to 2024
$2.6M
Defining STIM1 function at the Immunological SynapseR01AI152506 · NIAID · TEMPLE UNIV OF THE COMMONWEALTH · PI SOBOLOFF, JONATHAN A · 2020 to 2024
$2.0M
Prevention of arthritis-induced bone erosion by inhibiting osteoclast differentiation by the haloanilide, N-Methyl DichloropropionanilineR42AR074812 · NIAMS · EXESALIBERO, INC. · PI BARNETT, JOHN B · 2019 to 2021
$1.7M
Special Becton Dickinson Fortessa Flow CytometerS10OD016165 · OD · WEST VIRGINIA UNIVERSITY · PI CUFF, CHRISTOPHER F · 2013 to 2013
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Targeting TRPC channels for control of arthritis-induced bone erosion. · full record | OpenQuestion